

## Supporting information

### Peptide/ $\beta$ -peptoid hybrids with activity against vancomycin-resistant enterococci: Influence of hydrophobicity and structural features on antibacterial and hemolytic properties

Martin Vestergaard<sup>1</sup>, Bolette Skive <sup>1</sup>, Ilona Domraceva,<sup>3</sup> Hanne Ingmer<sup>1</sup> & Henrik Franzyk<sup>2\*</sup>

1. Department of Veterinary and Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Stigbøjlen 4, DK-1870 Frederiksberg C, Denmark.
2. Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2100 Copenhagen, Denmark.
3. Latvian Institute of Organic Synthesis, Aizkraukles 21, 1006, Riga, Latvia

**Supplementary Table S1.** Screening of 20 peptidomimetics against Enterococci.

Initial screening of peptidomimetics at a single concentration (32 µg/ml) against multiple *E. faecium* and *E. faecalis* strains. Compounds marked in blue were selected for further studies.

Inhibition at 48 h		Growth after 48 h		Growth after 24 h				
		<i>E. faecium</i>				<i>E. faecalis</i>		
No.	Sequence	ATCC 19434	3978	2961	1798	ATCC 29212	37216	38262
1	Ac-[hArg-βNPhe] <sub>8</sub> -NH <sub>2</sub>							
	Ac-[hArg-βNspe] <sub>6</sub> -NH <sub>2</sub>							
2	Ac-[hArg-βNsce] <sub>6</sub> -NH <sub>2</sub>							
3	SpermineAc-[hArg-βNspe-Lys-βNspe] <sub>3</sub> -NH <sub>2</sub>							
	NDab-[hArg-βNspe-Lys-βNspe] <sub>3</sub> -NH <sub>2</sub>							
	TODA-[hArg-βNspe-Lys-βNspe] <sub>3</sub> -NH <sub>2</sub>							
4	H-[hArg-βNspe-Lys-βNspe] <sub>4</sub> -NH <sub>2</sub>							
	Ac-[hArg-Nspe-Lys-Nspe] <sub>3</sub> -NH <sub>2</sub>							
5	Ac-[hArg-βNsce-Lys-βNspe] <sub>3</sub> -NH <sub>2</sub>							
6	Cinn-[hArg-βNspe-Lys-βNspe] <sub>3</sub> -NH <sub>2</sub>							
	H-(NLys-Phe) <sub>8</sub> -NH <sub>2</sub>							
	SpermineAc-(Lys-βNPhe) <sub>6</sub>							
	Ac-(Lys-βNspe) <sub>8</sub> -NH <sub>2</sub>							
7	H-[Lys-βNPhe(F)] <sub>8</sub> -NH <sub>2</sub>							
8	H-[Lys-βNPhe(F <sub>3</sub> )] <sub>6</sub> -NH <sub>2</sub>							
9	H-[Lys-βNCha] <sub>8</sub> -NH <sub>2</sub>							
10	Oct-[Lys-βNspe] <sub>6</sub> -NH <sub>2</sub>							
11	Lau-[Lys-βNPhe] <sub>6</sub> -NH <sub>2</sub>							
	Ac-[NLys-Trp] <sub>8</sub> -NH <sub>2</sub>							
	Ac-[βNLys-Trp] <sub>8</sub> -NH <sub>2</sub>							

Abbreviations: Ac = acetyl; Cinn = cinnamoyl; hArg=homoarginine; Lau = lauroyl; βNCha = N-cyclohexylmethyl-β-alanine; NLys = N-(4-aminobutyl)-glycine; βNLys = N-(4-aminobutyl)-β-alanine; βNPhe = N-benzyl-β-alanine; βNPhe(F) = N-(4-fluorobenzyl)-β-alanine; βNPhe(F<sub>3</sub>) = N-(3,4,5-trifluorobenzyl)-β-alanine; βNsce=N-(S)-1-cyclohexylethyl-β-alanine; βNspe=N-(S)-1-phenylethyl-β-alanine; Oct = octanoyl; SpermineAc = H<sub>2</sub>N(CH<sub>2</sub>)<sub>3</sub>NH(CH<sub>2</sub>)<sub>4</sub>NH(CH<sub>2</sub>)<sub>3</sub>NHCH<sub>2</sub>(C=O)-; TODA = H<sub>3</sub>CO(CH<sub>2</sub>)<sub>2</sub>O(CH<sub>2</sub>)<sub>2</sub>OCH<sub>2</sub>(C=O)-.

**Supplementary Table S2.** Drug combinations of peptidomimetics with conventional antibiotics.  
N.D.: Not determined

Antibiotic	Peptidomimetic (+/- 0.5x MIC)	MIC µg/ml			
		<i>E. faecium</i>	<i>E. faecalis</i>	<i>E. faecium</i>	<i>E. faecium</i>
		ATCC 19434	ATCC 29212	2961	1798
Vancomycin	-	1-2	2-4	>256	>256
	+ 2	2	4	>256	>256
	+ 5	2	4	>256	>256
	+ 10	2	2	>256	>256
Gentamicin	-	64	16	N.D.	N.D.
	+ 2	64	16	N.D.	N.D.
	+ 5	32	16	N.D.	N.D.
	+ 10	64	16	N.D.	N.D.
Ciprofloxacin	-	4-8	0.5-1	N.D.	N.D.
	+ 2	4-8	1	N.D.	N.D.
	+ 5	4-8	0.5-1	N.D.	N.D.
	+ 10	4-8	0.5-1	N.D.	N.D.
Linezolid	-	2	2	N.D.	N.D.
	+ 2	2	2	N.D.	N.D.
	+ 5	2	2	N.D.	N.D.
	+ 10	2	2	N.D.	N.D.
Rifampicin	-	8	1	N.D.	N.D.
	+ 2	8	1	N.D.	N.D.
	+ 5	8	1	N.D.	N.D.
	+ 10	1-2	0.5-1	N.D.	N.D.
Azithromycin	-	4-8	1-2	N.D.	N.D.
	+ 2	4-8	1	N.D.	N.D.
	+ 5	4-8	1-2	N.D.	N.D.
	+ 10	4-8	1-2	N.D.	N.D.

**Supplementary Table S3.** Minimum bactericidal concentration for three selected peptidomimetics.

Compound	MV388 (µg/ml)	MV269 (µg/ml)
<b>2</b>	4-8	8
<b>5</b>	128	16
<b>10</b>	16	32

**Supplementary Table S4.** Strains used in this study.

Identity no.	Strain name	Source
MV270	<i>E. faecium</i> D344R	[1]
MV388	<i>E. faecium</i> ATCC 19434	ATCC
MV389	<i>E. faecium</i> 3978	Human clinical isolate
MV390	<i>E. faecium</i> 2961	Human clinical isolate
MV391	<i>E. faecium</i> 1798	Human clinical isolate
MV269	<i>E. faecalis</i> ATCC 29212	ATCC
MV392	<i>E. faecalis</i> 37216	Veterinary isolate
MV393	<i>E. faecalis</i> 38262	Veterinary isolate
MV394	<i>E. faecalis</i> 39002	Veterinary isolate

**Reference:**

1. Williamson, R.; Le Bouguénec, C.; Gutmann, L.; Horaud, T. One or two low affinity penicillin-binding proteins may be responsible for the range of susceptibility of *Enterococcus faecium* to benzylpenicillin. *Microbiology* **1985**, *131*, 1933-1940, doi:10.1099/00221287-131-8-1933.